A Long-term Follow-up Study in Patients Who Received BEAM-101
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-37
SponsorBeam Therapeutics Inc.
About this trial
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
Eligibility criteria
Qualifiers
Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit.
Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements.
Disqualifiers
There are no exclusion criteria for this study.
Trial design
Treatments tested in this trial
- Long-Term Follow-up Study of patients who received BEAM-101
Treatment groups
50 Participants
are divided into 1 treatment groupLocations
17Alabama
University of Alabama at Birmingham35233, Birmingham United States
Arizona
Phoenix Children's Hospital85016, Phoenix United States
Florida
Mayo Clinic Florida32224, Jacksonville United States
Georgia
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston30329, Atlanta United States
Sponsors and collaborators
Beam Therapeutics Inc.
Lead sponsor
Source ClinicalTrials.gov